Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Conditions

• Retroperitoneal Liposarcoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.

Key Dates

Start date

Sep 5, 2024

Status verified

Jan 2026

Primary completion

Dec 31, 2032

Completion

Dec 31, 2032

Study Design

Enrollment

100 participants (estimated)

Arms

• Arm: Surgery with preoperative radiotherapy
  This includes patient who have had any chemotherapy.
• Arm: Surgery without preoperative radiotherapy
  This includes patients who had surgery alone, surgery with postoperative radiotherapy and/or any chemotherapy.

Primary Outcome Measure

Abdominopelvic recurrence-free survival (ARFS). . [ Time Frame: Up to 5 years. ]

Central Contacts

• Janina Chapman
  61414316490
  [email protected]

Locations (3)

Find similar trials in Atlanta, GA

Related Studies

• Genomic Risk in Retroperitoneal Sarcoma
  Recruiting · Fox Chase Cancer Center · Philadelphia, Pennsylvania